FDA Grants Fast Track Designation to Nemvaleukin Alfa for Mucosal Melanoma
Immunotherapy agent nemvaleukin alfa was granted an FDA fast track designation for the treatment of patient’s mucosal melanoma for previously undergone treatment with an anti-PD-L1 therapy.